BioSpace News Archive

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that members of its Cryptography & Information Security (CIS) Lab and of the NTT Social Informatics Laboratories co-authored 10 papers that are being presented at Eurocrypt 2021, one of three flagship conferences organized by the International Association for Cryptologic Research (IACR).

Transcat, Inc. announced that it will release its second quarter fiscal year 2022 results after the close of financial markets on Tuesday, November 2, 2021.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at Dawson James Securities’ 6th Annual Small Cap Growth Conference.

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for its IMC™ Summit: Uncovering Spatial Biology.

Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the release of preliminary data from 69 subjects participating in the Prospective, Multi-Center Evaluation of the Clinical Utility (PRECIsE) – a post-market, multi-center clinical trial of its Ion endoluminal system.

Nanjing Bioheng Biotech Co., Ltd, announced that Professor Carl June, an authoritative cancer immunologist and “Pioneer of Chimeric Antigen Receptor T cells,” officially joined the Bioheng scientific advisory board and acted as chairman.

Enveda Biosciences announced today the appointment of a new Chief Platform Officer (CPO), August Allen .

SPR Therapeutics announced today it has raised $37 million in an oversubscribed Series D growth equity financing.

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8, 2021.